Our new pick is: AXXE – Axxess Pharma
Good Morning Readers And Welcome New Subscribers!
AXXE reminds us of one of our biggest recent winners, PMCB.
PMCB had traded sideways around .10c for a while with solid trading activity ant interest before taking off and hitting a high of .26c during a multi week run!
AXXE has traded as high as .35c this year and has made some nice moves during the year, including a recent 200% multi day run from .06 to .18c, fortunately, it hasnt been able to hold its gains and is sitting just under .09c a share now.
Axxess Pharma Inc. is a Nevada Corporation operating through its wholly owned Canadian Subsidiary: Axxess Pharma Canada Inc., headquartered in Toronto. Axxess is a specialty Health Care Products Company dedicated to improving health and quality of life by offering select medicines, nutritional supplements and over the counter remedies all across the Americas. Axxess’s goal is to bring additional products to the market and provide new, innovative options for better health spanning areas such as high cholesterol, blood pressure, acute pain — to optimal health management through improved nutritional supplements.
AXXE is a licensee for the TapouT brand and the company has been distributing its own Tapout-branded line of muscle supplements and pain relief supplements. AXXE has just released news this morning! AXXE signs major manufacturing, marketing and distribution agreement with Chinese manufacturer.
Under the agreement, Tong will be launching its own brand of products using Axxess’ patented formula. Tongs products will be sold online, world-wide and in select retail outlets. Axxess Pharma projects minimum sales of $525,000 USD in the first year and $4,308,000 USD in the initial 5 year term of the license.
“This deal represents a major milestone for Axxess Pharma, and validates the value of our Intellectual Property. Revenues are expected to begin in the third quarter 2015 and accelerate year over year.” stated Dr. Bagi President of Axxess Pharma Inc.
AXXE’s largest development was its recent FDA approval to sell omega 3 fish oil, muscle growth, muscle recovery supplements and turbo blend protein power on March 16th, 2015.
Axxess’s FDA approval will not only allow this new line of products to be distributed nationally into big box retail chain stores, but will also facilitate entry into more regulated markets such as Mexico and other foreign jurisdictions. Axxess expects the latest FDA approval to accelerate the pace of current overseas sales.Management is now projecting, year over year sales from March 2015 to March 2016 of $2.5M.
Dr. Daniel Bagi, President of Axxess Pharma, Inc. stated: “We are very excited to receive FDA approval to sell our latest line of all-natural TapouT supplements and protein powders within the US. Our all-natural products will be sold under the globally recognized name TapouT, and will have the words ‘FDA Approved’ on every label. Our unique high potency Omega-3 fish oil supplements is anticipated to be one of our top sellers both in the US and internationally.”
On April 15th AXXE provided a shareholder update.
Below are the additional accomplishments by Axxess Pharma in 2015.
Due to the vast amount of information available for this company we feel it would be hard to cover every single detail so here are some links to continue your DD with:
AXXE continues to be one of the more actively traded OTC stocks with one heck of a story. Its amazing it has managed to stay so cheap even after the FDA approval of its products.
AXXE has shown what it can do just 1 month ago when it flew 200% in a few days.
With all of these great developments and AXXE anticipating sales from March 2015 to March 2016 to reach 2.5M, how can you not be excited for the future of AXXE?
This newsletter is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Owners of this newsletter may buy and sell shares at the open market at any time during this email program. Because of this conflict, individuals are strongly encouraged to not using this newsletter as the basis for any investment decision. We are not responsible for any losses you may incur while using this newsletter and its services. If you do not agree with this statement then please leave this service immediately. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a real licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment. We have been compensated six thousand dollars cash via wire transfer for this marketing awareness campaign on AXXE by a third party The Stock Alerts LLC.